[Zoladex in prostatic carcinoma].
Di Silverio
F
F
Dipartimento di Urologia U. Bracci, Università degli Studi La Sapienza, Roma, Italia.
Serio
M
M
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017273:Goserelin; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D006728:Hormones; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D002064:Buserelin
Zoladex nel carcinoma prostatico.